Elizabeth de Somer
Elizabeth de Somer is the chief executive of Medicines Australia, the peak body representing the pharmaceutical industry in Australia. She has been vocal about the growing concern that Australian patients are missing out on innovative medicines due to a complex approval process and chronic underinvestment in the Pharmaceutical Benefits Scheme, highlighting the urgent need for reforms in drug access and funding.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Australia | 1 | 6.00 | 0.08% | +0% | 25,499,884 | 19,615 | $1,380,000 | 1,062$ |
| Totals | 1 | 25,499,884 | 19,615 | $1,380,000 | 1,062$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Australia:
Elizabeth de Somer highlighted that cases like Powney's demonstrate Australia's decline in funding new medicines.
6